Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 121 publications
Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study.
Journal: Future oncology (London, England)
Published: August 30, 2026
Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma.
Journal: Expert opinion on investigational drugs
Published: April 23, 2026
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.
Journal: Blood cancer journal
Published: December 04, 2025
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.
Journal: American journal of hematology
Published: October 28, 2025
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.
Journal: Nature medicine
Published: October 03, 2025
Operationalization and Use of Bispecific T-Cell-Engaging Antibodies in Community Practices: Multidisciplinary Perspectives on Developing Logistics and Workflow for Cytokine Release Syndrome Management.
Journal: Journal of the advanced practitioner in oncology
Published: August 07, 2025
Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data Analysis.
Journal: European journal of haematology
Published: July 14, 2025
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions.
Journal: Expert opinion on investigational drugs
Published: July 14, 2025
Last Updated: 09/26/2026